Literature DB >> 16957081

Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors.

Jelena Mojsilovic-Petrovic1, Goo-Bo Jeong, Amanda Crocker, Amrita Arneja, Samuel David, David S Russell, David Russell, Robert G Kalb.   

Abstract

The death of motor neurons in amyotrophic lateral sclerosis (ALS) is thought to result from the interaction of a variety of factors including excitotoxicity, accumulation of toxic proteins, and abnormal axonal transport. Previously, we found that the susceptibility of motor neurons to excitotoxic insults can be limited by inhibiting signals evoked by brain-derived neurotrophic factor (BDNF) activation of the receptor tyrosine kinase B (TrkB). Here we show that this can be achieved by direct kinase inhibition or by blockade of a transactivation pathway that uses adenosine A2a receptors and src-family kinases (SFKs). Downstream signaling cascades (such as mitogen-activated protein kinase and phosphatidylinositol-3 kinase) are inhibited by these blockers. In addition to protecting motor neurons from excitotoxic insult, these agents also prevent toxicity that follows from the expression of mutant proteins (G85R superoxide dismutase 1; G59S p150(glued)) that cause familial motor neuron disease. TrkB, adenosine A2a receptors, and SFKs associate into complexes in lipid raft and nonlipid raft membranes and the signaling from lipids rafts may be particularly important because their disruption by cholesterol depletion blocks the ability of BDNF to render motor neurons vulnerable to insult. The neuroprotective versatility of Trk antagonism suggests that it may have broad utility in the treatment of ALS patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957081      PMCID: PMC6674510          DOI: 10.1523/JNEUROSCI.1856-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  53 in total

1.  Signaling events in axons and/or dendrites render motor neurons vulnerable to mutant superoxide dismutase toxicity.

Authors:  Goo-Bo Jeong; Jelena Mojsilovic-Petrovic; Marco Boccitto; Robert Kalb
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

2.  Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

Authors:  M Cazorla; J M Arrang; J Prémont
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  The in vivo contribution of motor neuron TrkB receptors to mutant SOD1 motor neuron disease.

Authors:  Jinbin Zhai; Weiguo Zhou; Jian Li; Christopher R Hayworth; Lei Zhang; Hidemi Misawa; Rudiger Klein; Steven S Scherer; Rita J Balice-Gordon; Robert Gordon Kalb
Journal:  Hum Mol Genet       Date:  2011-08-04       Impact factor: 6.150

4.  FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases.

Authors:  Jelena Mojsilovic-Petrovic; Natalia Nedelsky; Marco Boccitto; Itzhak Mano; Savvas N Georgiades; Weiguo Zhou; Yuhong Liu; Rachael L Neve; J Paul Taylor; Monica Driscoll; Jon Clardy; Diane Merry; Robert G Kalb
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

5.  Role of GluR1 in activity-dependent motor system development.

Authors:  Lei Zhang; Joachim Schessl; Markus Werner; Carsten Bonnemann; Guoxiang Xiong; Jelena Mojsilovic-Petrovic; Weiguo Zhou; Akiva Cohen; Peter Seeburg; Hidemi Misawa; Aditi Jayaram; Kirkwood Personius; Michael Hollmann; Rolf Sprengel; Robert Kalb
Journal:  J Neurosci       Date:  2008-10-01       Impact factor: 6.167

Review 6.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 7.  GM1 Ganglioside: Past Studies and Future Potential.

Authors:  Massimo Aureli; Laura Mauri; Maria Grazia Ciampa; Alessandro Prinetti; Gino Toffano; Cynthia Secchieri; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2015-03-12       Impact factor: 5.590

8.  GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors.

Authors:  Catarina A R V Gomes; Patrícia F Simões; Paula M Canas; César Quiroz; Ana M Sebastião; Sergi Ferré; Rodrigo A Cunha; Joaquim A Ribeiro
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

9.  Tuning and fine-tuning of synapses with adenosine.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.

Authors:  Maxime Cazorla; Anne Jouvenceau; Christiane Rose; Jean-Philippe Guilloux; Catherine Pilon; Alex Dranovsky; Joël Prémont
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.